Prosecution Insights
Last updated: April 19, 2026
Application No. 16/446,718

Process For Formation of Emulsion Containing Liquid Crystal Structure

Non-Final OA §103
Filed
Jun 20, 2019
Examiner
SOROUSH, LAYLA
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Kenvue Brands LLC
OA Round
7 (Non-Final)
40%
Grant Probability
Moderate
7-8
OA Rounds
3y 10m
To Grant
83%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allow Rate
349 granted / 868 resolved
-19.8% vs TC avg
Strong +43% interview lift
Without
With
+43.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
53 currently pending
Career history
921
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
50.3%
+10.3% vs TC avg
§102
12.5%
-27.5% vs TC avg
§112
12.9%
-27.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 868 resolved cases

Office Action

§103
DETAILED ACTION Status of Application Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission, filed on 8/5/2025, has been entered. The original restriction election is carried over from the response to the office action mailed on June 28, 2021.Claims 1, 3-4, 9-10, 12-13 are pending in this action. Claim 14 have been cancelled. Claims 1, has been amended. No new claims have been added. No new matter was added. Claims 1, 3-4, 9-10, 12-13 are herein acted on the merits. Any rejection or objection not reiterated in this action is withdrawn. Applicant's amendments necessitated new ground(s) of rejection presented in this office action. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Application Priority This application filed 06/20/2019, claims priority to PRO 62/688,714 filed 06/22/2018. Information Disclosure Statement No new information disclosure statement(s) (IDS) filed. Response to Arguments Applicant’s arguments with respect to 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as applied to claims 1 and 14 is persuasive in view of the amendments made to the claims. The rejection is herewith withdrawn. Applicant’s arguments with respect to 35 U.S.C. 103 as being unpatentable Klacsová et al. (The effect of aliphatic alcohols on fluid bilayers in unilamellar DOPC vesicles--a small-angle neutron scattering and molecular dynamics study. Biochim Biophys Acta. 2011 Sep;1808(9):2136-46. doi: 10.1016/j.bbamem.2011.04.010. Epub 2011 Apr 29 - IDS) in view of Hassan (US 20080161588 A1) of claim(s) 1, 3-4, 6-7 is not persuasive. The rejection is herewith maintained. See response to arguments below. Applicant’s arguments with respect to the 35 U.S.C. 103 as being unpatentable Klacsová et al. (The effect of aliphatic alcohols on fluid bilayers in unilamellar DOPC vesicles--a small-angle neutron scattering and molecular dynamics study. Biochim Biophys Acta. 2011 Sep;1808(9):2136-46. doi: 10.1016/j.bbamem.2011.04.010. Epub 2011 Apr 29 - IDS) in view of Hassan (US 20080161588 A1), as applied to claims 1, 3-4, and 6-7 and further in view of Dierker (US 2008/0161418 A1) of claim(s) 9-10, 12-13 is not persuasive. The rejection is herewith maintained. Applicant argues Klacsová and Hassan do not teach the rotor and stator. Further Applicant argues in order to achieve successful intercalation the proper homogenizer is needed. Then Applicant points to failed batches and batches that have no agglomerates. The Examiner respectfully points out that the comparisons made in the examples do not commensurate in scope with the claims. Specifically, the Applicant states the process as claimed advantageously provides a process for producing liquid crystal structures, comprising cetyl alcohol and potassium cetyl phosphate, hydrogenated palm glycerides without visible agglomerates, while having good appearance, stability profile and skin barrier protection. The arguments are not persuasive. The following rejections are made: Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 3-4, and 14 are rejected under 35 U.S.C. 103 as being unpatentable over Klacsová et al. (The effect of aliphatic alcohols on fluid bilayers in unilamellar DOPC vesicles--a small-angle neutron scattering and molecular dynamics study. Biochim Biophys Acta. 2011 Sep;1808(9):2136-46. doi: 10.1016/j.bbamem.2011.04.010. Epub 2011 Apr 29 - IDS) in view of Hassan (US 20080161588 A1). A composition prepared according to the process comprising contacting a mixture comprising (1) a negatively charged phospholipid and/or phospholipid derivative; and (2) a fatty alcohol with a rotor and stator homogenizer and homogenizing the mixture using a three-stage rotor and stator homogenizer configuration, wherein the phospholipid or phospholipid derivative is selected from the group consisting of dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, di stearoylphosphatidylglycerol, dioleoylphosphatidylglycerol oleoylpalmitoylphosphatidylglycerol, dipalmitoylphosphatidylserine dioleoylphosphatidylserine, dimyristoylphosphatidylinositol, dipalmitoylphosphatidylinositol phosphatidylethanolamine, di stearoylphosphatidylinositol, dioleoylphosphatidylinositol dimyristoylphosphatidylserine, and distearoylphosphatidylserine and wherein the fatty alcohol consists of cetyl alcohol. Klacsová et al. teaches dioleoylphosphatidylcholine:dioleoylphosphatidylserine (PCPS, DOPC:DOPS = 24.7 mol:mol) bilayers in extruded unilamellar vesicles with incorporated aliphatic alcohols (CnOH, n = 8–18 is the even number of carbons in alkyl chain) (reads on the (2) fatty alcohol emollient wax). The small amount of DOPS present in DOPC bilayers charges the bilayer surface negatively (reads on the negatively charged phospholipid) and thus prevents oligolamellar vesicle formation during extrusion and vesicle aggregation after extrusion, while it does not affect the structure of DOPC bilayer itself (Abstract, and p2137 left col, last para). The samples were hydrated with heavy water and homogenized by vigorous vortex mixing (p2137 right col 2.2. Contrast variation samples). (The product of the DOPC bilayers and aliphatic alcohol reads on the composition of claim 4). The reference uses egg yolk phosphatidylcholine.(Introduction para 2) The reference also teaches incorporated aliphatic alcohols (CnOH, n = 8–18 is the even number of carbons in alkyl chain) (see abstract C16 reads on the cetyl alcohol of the claim 1. While the reference teaches that samples were homogenized by vigorous vortex mixing, the reference fails to specify a three stage rotor and the energy of at least about 0.18 hp/lb/min. Hassan et al. teaches the making of colloids or emulsions for a range of products including pourable vegetable oils, frying oil, peanut butter stabilizers, cosmetics, etc [0036]. The method of making can include using a disperser. The disperser IKA model DR 2000/4 is a high shear, three stage dispersing device useful in making such. Three rotors in combination with a stator are aligned in series to create the dispersion of hydrogen in liquid medium comprising base oil. Mixed high shear device inlet stream enters the high shear device at a high shear device inlet and enters a first stage rotor/stator combination having circumferentially spaced first stage shear openings. The coarse dispersion exiting the first stage enters the second rotor/stator stage, having second stage shear openings. The reduced bubble-size dispersion emerging from the second stage enters the third stage rotor/stator combination having third stage shear openings. The dispersion exits the high shear device via a high shear outlet as high shear device dispersion outlet stream. In embodiments, the shear force increases stepwise longitudinally along the direction of the flow [0116]. “The stator can be adjusted to obtain the desired gap between the rotor and the stator. The grooves change directions in each stage for increased turbulence.” [0117] Reads on increasing turbulence in each stage). A discrete reactor is desirable in some applications, however, to allow for increased residence time, agitation and heating and/or cooling. [0122] (Renders obvious modifying a discrete reactor to allow for increased residence time). Hassan describes “high shear device delivers a certain amount of energy per volume/weight of fluid. In embodiments, the high shear device delivers at least 300 L/h (or 5L/min, depending on agent i.e. water: 11lb/min) with a power consumption of 1.5 kW (or 2hp) at a nominal tip speed of at least 4500 fpm[0119], (in other words the high shear device delivers an energy of at least about 0.18hp/lb/min). One of ordinary skill in the art at the time of filing would have been motivated to incorporate the specific disperser IKA model DR 2000/4 to homogenize the formulation of Klacsová et al. The motivation to use the disperser IKA model DR 2000/4 is because Klacsová et al. teaches the samples were homogenized by vigorous vortex mixing and Hassan et al. teaches IKA model DR 2000/4 is a high shear, three stage dispersing device which creates dispersions of hydrogen in liquid medium comprising base oil, with reduced bubble-size useful for cosmetics. The skilled artisan would have had reasonable expectation of successfully achieving similar efficacy and results. Claims 9-10, 12-13 are rejected under 35 U.S.C. 103 as being unpatentable over Klacsová et al. (The effect of aliphatic alcohols on fluid bilayers in unilamellar DOPC vesicles--a small-angle neutron scattering and molecular dynamics study. Biochim Biophys Acta. 2011 Sep;1808(9):2136-46. doi: 10.1016/j.bbamem.2011.04.010. Epub 2011 Apr 29 - IDS) in view of Hassan (US 20080161588 A1), as applied to claims 1, 3-4, and 14 and further in view of Dierker (US 2008/0161418 A1) . Klacsová et al. and Hassan are as discussed above. Klacsová et al. and Hassan fail to teach the specific composition of claim 9-10, 12-13. Dierker teaches a cosmetic composition (see the first composition in the table) containing 1.0 wt.% of cocoglyceride (instant emollient), 5.0 wt.% of caprylic/capric triglyceride (instant emollient), 6.0 wt.% of aiethyidecane (instant emollient), 0.5 wt.% of potassium cetyl phosphate (instant emulsifier), 0.3 wt.% of carbomer (instant gelling agent) and water. In addition to those components above (which represent instant emollient, emulsifier, gelling agent and water), Dierker’s composition a/so contains glycerol stearate (Cutine GMS-V), glycerine and dimethicone. Dierker states ([(0034]) that glycerol esters of higher fatty acids (such as glycerol stearate) are being used to improve the consistency of cosmetics With respect to instant 1.5-3% of an emollient wax, Dierker’s cosmetic composition discussed above contains 5.0 wt.% of Emulgade PL68/50 (a mixture of 50% cetearyl glucoside and 50% cetearyl alcohol (cetearyl alcohol is a mixture of cetyl alcohol (instant emollient wax) and stearyl alcohol)). Since there is 5 wt.% of Emulgade 68/50 present in Dierker’s first composition, this means that there are 2.5 wt.% of cetearyl glucoside and 2.5 wt.% of cetearyl alcohol present in Dierker’s first composition. Furthermore, since ceteary| alcohol is a mixture of cetyl alcohol and stearyl alcohol, this means that the amount for the cetyl alcohol present in the mixture of cetyl alcohol and stearyl alcohol (as contained in Dierker’s 5.0 wt.% of Emulgade PL 68/50) would have to be greater than 0 wt.% and less than 2.5 wt.%. Such range for the cetyl alcohol (instant emollient wax) overlaps with instant range of 1.5-3% for the emollient wax, thus rendering instant range prima facie obvious. In the case “where the [claimed] ranges overlap or lie inside ranges disclosed by the prior art,” a prima facie case of obviousness would exist which may be overcome by a showing of unexpected results, In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976) Dierker’s cosmetic composition discussed above contains (i) 12.0 wt.% of the sum of cocoglyceride, caprylic/capric triglyceride and diethyldecane (instant emollients), (ii) greater than 0 wt.% and less than 2.5 wt.% of cetyl alcohol (instant emollient wax), (iii) 0.5 wt.% of potassium cetyl phosphate (instant emulsifier) and (iv) 0.3 wt.% of carbomer (instant gelling agent). Dierker’s cosmetic composition as discussed above contains emollients in the amount of 12.0 wt.%. However, in [0031], Dierker clearly teaches that its oil/emollients can be present in the amount that ranges from 1 to 50 wt.% (in particular, 0-8 wt.%). Dierker’s cosmetic composition contains 0.3 wt.% of carbomer (instant gelling agent). The amount 0.3 wt.% for the carbomer is very close to the lower end of instant ranges of 0.4-0.6% of claim 9, thus rendering instant range prima facie obvious. Where the claimed ranges and prior art do not overlap but are close enough that one skilled in the art would have expected them to have the same properties, a prima facie case of obviousness would exist which may be overcome by a showing of unexpected results, In re Titanium Metals Corporation of America v. Banner, 227 USPQ 773 (Fed. Cir. 1985). Thus, Dierker’s teaching renders obvious instant claim 9. Conclusion No claims allowed. Contact Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAYLA SOROUSH whose telephone number is (571)272-5008. The examiner can normally be reached on Monday thru Friday; 8:30 AM to 5:00 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Henry Asltrum-Acevedo, can be reached on (571)272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LAYLA SOROUSH/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Jun 20, 2019
Application Filed
Dec 07, 2021
Response Filed
Apr 09, 2022
Non-Final Rejection — §103
Jul 13, 2022
Response Filed
Oct 22, 2022
Final Rejection — §103
Jan 23, 2023
Response after Non-Final Action
Mar 01, 2023
Request for Continued Examination
Mar 03, 2023
Response after Non-Final Action
Jun 17, 2023
Non-Final Rejection — §103
Sep 11, 2023
Response Filed
Sep 29, 2023
Final Rejection — §103
Dec 14, 2023
Request for Continued Examination
Dec 18, 2023
Response after Non-Final Action
May 02, 2024
Non-Final Rejection — §103
Oct 08, 2024
Response Filed
Jan 31, 2025
Final Rejection — §103
Aug 05, 2025
Request for Continued Examination
Aug 06, 2025
Response after Non-Final Action
Nov 01, 2025
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12564593
TOPICAL FORMULATION FOR A JAK INHIBITOR
2y 5m to grant Granted Mar 03, 2026
Patent 12544343
TREATMENT OF INFLAMMATORY CONDITION IN MUCOUS MEMBRANE OR SKIN
2y 5m to grant Granted Feb 10, 2026
Patent 12544381
TOPICAL FORMULATION FOR JAK INHIBITOR
2y 5m to grant Granted Feb 10, 2026
Patent 12527731
ACRYLATE-FREE COSMETIC EMULSION
2y 5m to grant Granted Jan 20, 2026
Patent 12522587
CANCER TREATMENTS TARGETING CANCER STEM CELLS
2y 5m to grant Granted Jan 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

7-8
Expected OA Rounds
40%
Grant Probability
83%
With Interview (+43.0%)
3y 10m
Median Time to Grant
High
PTA Risk
Based on 868 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month